Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Aduhelm’s Post-Marketing Studies: At Least One More Data Dump Likely Required By NIH
Feb 21 2024
•
By
Sarah Karlin-Smith
Clinicaltrials.gov reporting requirements should help fill in some data gaps on Aduhelm despite end of commercialization. • Source: Shutterstock
More from United States
More from North America